Filing Details
- Accession Number:
- 0001209191-14-034322
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-05-15 17:45:28
- Reporting Period:
- 2014-05-13
- Filing Date:
- 2014-05-15
- Accepted Time:
- 2014-05-15 17:45:28
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1423824 | Alder Biopharmaceuticals Inc | ALDR | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1255743 | J James Bochnowski | C/O Delphi Ventures 3000 Sand Hill Rd., Bldg. 1, Suite 135 Menlo Park CA 94025 | No | No | Yes | No | |
1270734 | Deepika Pakianathan | C/O Delphi Ventures 3000 Sand Hill Rd., Bldg 1, Suite 135 Menlo Park CA 94025 | Yes | No | Yes | No | |
1270735 | A Douglas Roeder | C/O Delphi Ventures 3000 Sand Hill Rd., Bldg., Suite 135 Menlo Park CA 94025 | No | No | Yes | No | |
1271389 | L David Douglass | C/O Delphi Ventures 3000 Sand Hill Rd., Bldg. 1, Suite 135 Menlo Park CA 94025 | No | No | Yes | No | |
1336922 | P L Vii Ventures Delphi | 3000 Sand Hill Road Building 1, Suite 135 Menlo Park CA 94025 | No | No | Yes | No | |
1346198 | Delphi Bioinvestments Vii Lp | 3000 Sand Hill Road Building 1, Suite 135 Menlo Park CA 94025 | No | No | Yes | No | |
1457493 | Delphi Management Partners Vii, L.l.c. | C/O Delphi Ventures 3000 Sand Hill Rd., Bldg. 1, Suite 135 Menlo Park CA 94025 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-05-13 | 2,463,894 | $0.00 | 2,463,894 | No | 4 | C | Indirect | By Delphi Ventures VII, L.P. |
Common Stock | Acquisiton | 2014-05-13 | 24,638 | $0.00 | 2,488,532 | No | 4 | C | Indirect | By Delphi BioInvestments VII, L.P. |
Common Stock | Acquisiton | 2014-05-13 | 346,535 | $10.00 | 2,835,067 | No | 4 | P | Indirect | By Delphi Ventures VII, L.P. |
Common Stock | Acquisiton | 2014-05-13 | 3,465 | $10.00 | 2,838,532 | No | 4 | P | Indirect | By Delphi BioInvestments VII, L.P. |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | By Delphi Ventures VII, L.P. |
No | 4 | C | Indirect | By Delphi BioInvestments VII, L.P. |
No | 4 | P | Indirect | By Delphi Ventures VII, L.P. |
No | 4 | P | Indirect | By Delphi BioInvestments VII, L.P. |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series C Preferred Stock | Disposition | 2014-05-13 | 2,083,541 | $0.00 | 2,083,541 | $0.00 |
Common Stock | Series D Preferred Stock | Disposition | 2014-05-13 | 380,353 | $0.00 | 380,353 | $0.00 |
Common Stock | Series C Preferred Stock | Disposition | 2014-05-13 | 20,835 | $0.00 | 20,835 | $0.00 |
Common Stock | Series D Preferred Stock | Disposition | 2014-05-13 | 3,803 | $0.00 | 3,803 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- The preferred stock converted into common stock on a 1-for-1 basis upon the closing of the issuer's initial public offering and had no expiration date.
- The reported securities are directly owned by Delphi Ventures VII, L.P. ("DV VII). DMP VII is the general partner of DV VII and may be deemed to have sole voting and dispositive power over the securities held by DV VII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VII and may be deemed to share voting and dispositive power over the securities held by DV VII. Such persons and entities disclaim beneficial ownership of the securities held by DV VII, except to the extent of any pecuniary interest therein.
- The reported securities are directly owned by Delphi BioInvestments VII, L.P. ("DBI VII). DMP VII is the general partner of DBI VII and may be deemed to have sole voting and dispositive power over the securities held by DBI VII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VII and may be deemed to share voting and dispositive power over the securities held by DBI VII. Such persons and entities disclaim beneficial ownership of the securities held by DBI VII, except to the extent of any pecuniary interest therein.